Authorization

EQS-Adhoc: IGEA Pharma N.V.: GBC AG PUBLISHES INITIAL EQUITY RESEARCH REPORT WITH BUY RECOMMENDATION AND PRICE TARGET OF EUR 1.05

EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Research Update/Research Update


IGEA Pharma N.V.: GBC AG PUBLISHES INITIAL EQUITY RESEARCH REPORT WITH BUY RECOMMENDATION AND PRICE TARGET OF EUR 1.05


25-Nov-2021 / 23:10 CET/CEST


Release of an ad hoc announcement pursuant to Art. 53 LR


The issuer is solely responsible for the content of this announcement.



GBC AG PUBLISHES INITIAL EQUITY RESEARCH REPORT WITH BUY RECOMMENDATION AND PRICE TARGET OF EUR 1.05

Hoofddorp, the Netherlands, 25 November 2021. IGEA Pharma N.V. (SIX: IGPH) receives an analyst vote. On Monday 22nd the research house GBC AG (www.gbc-ag.de/) publishes its first coverage equity research on the Company and from now on, GBC analysts Matthias Greiffenbergerand Felix Haugg will cover the further development of Igea Pharma NV with continuous assessment.

In their study, GBC highlights how "The CBD market is growing strongly and with a focus on quality leadership and pure extraction" further stating that "IGEA Pharma's new business model should be able to occupy an attractive niche market positioning the company at the highest quality level with CBD from CO2 extraction".

In GBC's view "In the long term, significantly higher prices can probably be achieved, provided that their own brand is established" and the analyst comment that "In addition to the declared goal of becoming the quality leader, the company also plans to become the cost leader. and therefore, very high margins should be possible".
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2021    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728293031